You can buy or sell AXSM and other stocks, options, ETFs, and crypto commission-free!
Axsome Therapeutics, Inc. Common Stock, also called Axsome Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Read More Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Harry Boxer: 3 biotech stocks with momentum
Biotech stocks dominate our list of top charts to watch today. Axsome Therapeutics Inc. AXSM, -1.81% (AXSM) jumped $1.23 to $13.24 on 1.9 million shares Thursday. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. The stock is a little overbought in the short term — down only once in the last three weeks — but momentum is strong for a move toward $16. Support is at the March 19 low in...
Seeking AlphaMar 14
Axsome Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides
The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with their 2018 Q4 earnings call. 1 41 Click to enlarge Notes:...
Associated PressMar 14
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2018. “In 2018, we advanced our clinical programs and significantly expanded our CNS pipeline through the addition of new internally generated product...
-$0.30 per share
-$0.32 per share